 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1997 | Volume 127 Issue 12 | Pages 1089-1092
Background: Stable renal transplant recipients have an excess prevalence of hyperhomocysteinemia, which is a risk factor for arteriosclerosis.
Objective: To determine the effect of treatment with 1) vitamin B6 or 2) folic acid plus vitamin B12 on fasting and post-methionine-loading plasma total homocysteine levels in renal transplant recipients.
Design: Block-randomized, placebo-controlled, 2 x 2 factorial study.
Setting: University-affiliated transplantation program.
Patients: 29 clinically stable renal transplant recipients.
Intervention: Patients were randomly assigned to one of four regimens: placebo (n = 8); vitamin B6, 50 mg/d (n = 7); folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d (n = 7); or vitamin B6, 50 mg/d, folic acid, 5 mg/d, and vitamin B12, 0.4 mg/d (n = 7).
Measurements: Fasting and 2-hour post-methionine-loading plasma total homocysteine levels.
Results: Vitamin B6 treatment resulted in a 22.1% reduction in geometric-mean post-methionine-loading increases in plasma total homocysteine levels (P = 0.042), and folic acid plus vitamin B12 treatment caused a 26.2% reduction in geometric-mean fasting plasma total homocysteine levels (P = 0.027). These results occurred after adjustment for age; sex; and pretreatment levels of total homocysteine, B vitamins, and creatinine.
Conclusions: Vitamin B6 should be added to the combination of folic acid and vitamin B12 for effective reduction of both post-methionine-loading and fasting plasma total homocysteine levels in renal transplant recipients.
Author and Article Information
From The Jean Mayer USDA Human Nutrition Research Center, Boston, Massachusetts; Rhode Island Hospital, Providence, Rhode Island; and Memorial Hospital of Rhode Island, Pawtucket, Rhodc Island.
BRIEF COMMUNICATION
Treatment of Hyperhomocysteinemia in Renal Transplant Recipients
A Randomized, Placebo-Controlled Trial
Acknowledgments: The authors thank R&D Laboratories; Dr. Rhoda Makoff, for supplying the vitamin and placebo capsules; and Ms. Evelyn Tolbert, for technical support.
Grant Support: By a discretionary grant to Dr. Bostom from the Massachusetts/Rhode Island Affiliate of The National Kidney Foundation.
Requests for Reprints: Andrew G. Bostom, MD, MS, Department of General Internal Medicine, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860.
Current Author Addresses: Dr. Bostom: Department of General Internal Medicine, Memorial Hospital of Rhode Island, 111 Brewster Street, Pawtucket, RI 02860.
This article has been cited by other articles:
|
|
 |
|
  O. Midttun, S. Hustad, J. Schneede, S. E Vollset, and P. M Ueland Plasma vitamin B-6 forms and their relation to transsulfuration metabolites in a large, population-based study Am. J. Clinical Nutrition, July 1, 2007; 86(1): 131 - 138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Crowther Pathogenesis of Atherosclerosis Hematology, January 1, 2005; 2005(1): 436 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Steenge, P. Verhoef, and M. B. Katan Betaine Supplementation Lowers Plasma Homocysteine in Healthy Men and Women J. Nutr., May 1, 2003; 133(5): 1291 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Mason Biomarkers of Nutrient Exposure and Status in One-Carbon (Methyl) Metabolism J. Nutr., March 1, 2003; 133(3): 941S - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Sechi, C. Catena, L. Zingaro, A. Melis, and S. De Marchi Abnormalities of Glucose Metabolism in Patients With Early Renal Failure Diabetes, April 1, 2002; 51(4): 1226 - 1232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Bostom, P. F. Jacques, G. Liaugaudas, G. Rogers, I. H. Rosenberg, and J. Selhub Total Homocysteine Lowering Treatment Among Coronary Artery Disease Patients in the Era of Folic Acid-Fortified Cereal Grain Flour Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 488 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. van der Griend, D. H Biesma, and J.-D. Banga Postmethionine-load homocysteine determination for the diagnosis hyperhomocysteinaemia and efficacy of homocysteine lowering treatment regimens Vascular Medicine, February 1, 2002; 7(1): 29 - 33. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Fernandez-Miranda, M. Sanz, A. de la Calle, C. Loinaz, P. Gomez, P. Diaz-Rubio, A. G. de la Camara, and E. Moreno Determinants of Increased Plasma Homocysteine in 221 Stable Liver Transplant Patients Clin. Chem., November 1, 2001; 47(11): 2037 - 2040. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Tice, E. Ross, P. G. Coxson, I. Rosenberg, M. C. Weinstein, M. G. M. Hunink, P. A. Goldman, L. Williams, and L. Goldman Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond JAMA, August 22, 2001; 286(8): 936 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C McKinley, H. McNulty, J. McPartlin, J. Strain, K. Pentieva, M. Ward, D. G Weir, and J. M Scott Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete Am. J. Clinical Nutrition, April 1, 2001; 73(4): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. KASISKE, M. A. VAZQUEZ, W. E. HARMON, R. S. BROWN, G. M. DANOVITCH, R. S. GASTON, D. ROTH, J. D. SCANDLING JR., and G. G. SINGER Recommendations for the Outpatient Surveillance of Renal Transplant Recipients J. Am. Soc. Nephrol., October 1, 2000; 11(2007): S1 - S86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Bostom, D. Shemin, P. Bagley, Z. A. Massy, A. Zanabli, K. Christopher, P. Spiegel, P. F. Jacques, L. Dworkin, and J. Selhub Controlled Comparison of L-5-Methyltetrahydrofolate Versus Folic Acid for the Treatment of Hyperhomocysteinemia in Hemodialysis Patients Circulation, June 20, 2000; 101(24): 2829 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. BOSTOM Homocysteine: "Expensive Creatinine" or Important,Modifiable Risk Factor for Arteriosclerotic Outcomes in Renal TransplantRecipients? J. Am. Soc. Nephrol., January 1, 2000; 11(1): 149 - 151. [Full Text]
|
|
|
|
|
|
A. J. Beaulieu, R. Y. Gohh, H. Han, D. Hakas, P. F. Jacques, J. Selhub, and A. G. Bostom Enhanced Reduction of Fasting Total Homocysteine Levels With Supraphysiological Versus Standard Multivitamin Dose Folic Acid Supplementation in Renal Transplant Recipients Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2918 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. VANHOLDER and R. DE SMET Pathophysiologic Effects of Uremic Retention Solutes J. Am. Soc. Nephrol., August 1, 1999; 10(8): 1815 - 1823. [Full Text]
|
|
|
|
|
|
A. G. BOSTOM and B. F. CULLETON Hyperhomocysteinemia in Chronic Renal Disease J. Am. Soc. Nephrol., April 1, 1999; 10(4): 891 - 900. [Full Text]
|
|
|
|
|
|
M. R. Malinow, A. G. Bostom, and R. M. Krauss Homocyst(e)ine, Diet, and Cardiovascular Diseases : A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association Circulation, January 12, 1999; 99(1): 178 - 182. [Full Text] [PDF]
|
|
Article
